On August 19, 2026, Merck & Co. and Moderna, Inc. announced positive topline results from the pivotal Phase 3 INTerpath-001 clinical trial (NCT05933577), confirming that intismeran autogene (formerly V940 or mRNA-4157) in combination with Keytruda (pembrolizumab) met both its primary endpoint of Recurrence-Free Survival (RFS) and key secondary endpoint of Distant Metastasis-Free Survival (DMFS) versus Keytruda monotherapy in patients with completely resected high-risk Stage IIB–IV melanoma.
This readout represents a historic milestone for clinical oncology: INTerpath-001 is the first-ever randomized Phase 3 trial to succeed for an individualized neoantigen therapy (INT) and the first late-stage pivotal validation of an mRNA platform in cancer immunotherapy.
While clinical headlines have focused on the scientific vindication of mRNA cancer vaccines, biopharma commercialization executives and oncology market-access directors are viewing this readout through an entirely different lens: franchise defense ahead of the 2028 Keytruda patent cliff.
With IV Keytruda generating more than $28 billion in annual global revenue and facing U.S. loss of exclusivity (LOE) in 2028, intismeran autogene is not merely an adjuvant melanoma therapy. It is the lead asset in a multi-tumor franchise strategy designed to pair a bespoke, patent-protected, per-patient therapeutic with a soon-to-be-commoditized checkpoint inhibitor backbone.
What did INTerpath-001 show—and what is still under wraps?
The Phase 3 INTerpath-001 trial evaluated the addition of intismeran autogene to single-agent pembrolizumab control following complete surgical resection of Stage IIB, IIC, III, or IV cutaneous melanoma:
┌─────────────────────────────────────────────────────────────┐
│ PHASE 3 INTerpath-001 TRIAL (NCT05933577) │
│ Resected High-Risk Stage IIB - IV Cutaneous Melanoma │
└──────────────────────────────┬──────────────────────────────┘
│ 2:1 Randomization
┌──────────────────────┴──────────────────────┐
▼ ▼
┌──────────────────────────────┐ ┌──────────────────────────────┐
│ Intismeran + Pembrolizumab │ │ Pembrolizumab Monotherapy │
│ • Intismeran: 1 mg IM Q3W │ │ • Pembrolizumab alone │
│ (Up to 9 Doses) │ │ (approximately one year) │
│ • Keytruda: 400 mg IV Q6W │ │ │
│ (Up to ~1 Year) │ │ │
└──────────────┬───────────────┘ └──────────────┬───────────────┘
│ │
└──────────────────────┬──────────────────────┘
│
▼
┌─────────────────────────────────────────────────────────────┐
│ TOPLINE READOUT RESULTS │
├─────────────────────────────────────────────────────────────┤
│ • Primary Endpoint (RFS): Met with statistical significance │
│ • Key Secondary Endpoint (DMFS): Met with stat significance │
│ • Overall Survival (OS): Continuing for long-term maturity │
│ • Hazard Ratios / CI / Safety Tables: Awaiting congress │
└─────────────────────────────────────────────────────────────┘
The clinical progression from Phase 2b to Phase 3 establishes a consistent evidence ladder:
| Clinical Milestone / Trial | Patient Population & Sample Size | Primary & Secondary Outcomes | Hazard Ratio (HR) & Survival Metrics | Regulatory / Strategic Impact |
|---|---|---|---|---|
| Phase 2b Primary Analysis (KEYNOTE-942 / NCT03897881) | 157 patients with resected Stage III/IV melanoma | Recurrence-Free Survival (RFS) | RFS HR ~0.56 (44% reduction in recurrence or death) | Granted FDA Breakthrough Therapy Designation in 2023 |
| Phase 2b 5-Year Durability (ASCO 2026 / JCO Publication) | 157 patients; median follow-up 5 years | 5-Year RFS and Distant Metastasis-Free Survival (DMFS) | RFS HR = 0.51 (95% CI: 0.294–0.887; 49% risk cut) DMFS HR = 0.411 (95% CI: 0.200–0.843; 59% risk cut) |
Demonstrated that neoantigen-specific T-cell memory persists without late-emerging relapses |
| Phase 3 Topline Readout (INTerpath-001 / NCT05933577) | 1,137 randomized patients (Registry enrollment: 1,089) | RFS (Primary) and DMFS (Key Secondary) | Both endpoints met with statistical significance (numeric HRs withheld for congress) | Establishes pivotal proof-of-concept; sponsors preparing FDA and global regulatory filings |
Enrollment Accounting Disclosed
A minor discrepancy between data sources is standard in oncology registries: Merck and Moderna's press release announced 1,137 randomized patients, whereas the ClinicalTrials.gov relational dataset (snapshot 2026-07-24) records an enrollment target of 1,089 participants with status marked as ACTIVE_NOT_RECRUITING. Both figures are carried with their sources; registry enrollment fields routinely trail the final randomization count in a global multi-center trial.
What Data Remain Withheld?
The August 19 announcement was strictly a qualitative topline press release. The companies have not yet released:
- Point estimates for the Phase 3 RFS and DMFS hazard ratios.
- 2-year and 3-year landmark recurrence-free survival rates.
- Subgroup analyses across Stage IIB/C versus Stage III/IV cohorts.
- Comprehensive safety tables detailing immune-related adverse events (irAEs) versus injection-site reactogenicity.
- Overall survival (OS) data, which remain immature and continue to be monitored per protocol.
For background on the broader landscape of RNA modalities, see our analysis of mRNA vaccine pipeline clinical trials 2026 and RNA therapeutics clinical trials 2026.
How does an individualized neoantigen therapy actually get made?
Unlike conventional oncology biologics that are manufactured in 10,000-liter bioreactors and distributed as standardized vials, intismeran autogene is a strictly bespoke, single-patient, single-batch drug product.
Every dose of intismeran is custom-designed to target up to 34 patient-specific neoantigens identified from the unique somatic mutational signature of that individual's surgically resected tumor.
┌─────────────────────────────────────────────────────────────┐
│ ONE-PATIENT-ONE-DRUG MANUFACTURING WORKFLOW │
└──────────────────────────────┬──────────────────────────────┘
│
┌──────────────────┬─────────────────────────┼─────────────────────────┬──────────────────┐
│ │ │ │ │
▼ ▼ ▼ ▼ ▼
┌──────────────────┐┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐┌──────────────────┐
│ 1. Surgical ││ 2. Next-Gen │ │ 3. Epitope │ │ 4. mRNA ││ 5. Cold-Chain │
│ Resection ││ Sequencing │ │ Prediction │ │ Synthesis ││ Delivery │
├──────────────────┤├──────────────────┤ ├──────────────────┤ ├──────────────────┤├──────────────────┤
│ Tumor tissue + ││ Whole-exome + │ │ AI algorithms │ │ Custom mRNA ││ Frozen vials │
│ blood PBMC sample││ RNA-seq identify │ │ rank top 34 HLA- │ │ synthesized in ││ shipped to site; │
│ sent to central ││ tumor somatic │ │ restricted │ │ LNPs; sterile ││ 1 mg IM every │
│ genomics lab ││ mutations │ │ immunogenic marks│ │ batch release ││ 3 weeks x 9 doses│
└──────────────────┘└──────────────────┘ └──────────────────┘ └──────────────────┘└──────────────────┘
The manufacturing and delivery sequence operates across five highly coordinated stages:
- Biopsy & Surgical Sample Intake: Following complete resection, fresh-frozen tumor tissue along with a peripheral blood mononuclear cell (PBMC) sample is shipped via temperature-controlled logistics to Moderna’s centralized sequencing facility.
- Genomic Sequencing & Bioinformatic Filtering: High-throughput next-generation sequencing (whole-exome sequencing and RNA sequencing) compares the tumor genome against germline DNA, cataloging all non-synonymous somatic mutations.
- Neoantigen Prediction Algorithm: Proprietary machine-learning algorithms model the patient’s specific Human Leukocyte Antigen (HLA) haplotype. The algorithm predicts which somatic mutations will produce peptides with high-affinity binding to Major Histocompatibility Complex (MHC) Class I and Class II molecules, selecting up to 34 optimal neoantigen sequences.
- Custom mRNA Transcription & Lipid Formulation: A single contiguous mRNA molecule encoding the 34 concatemerized neoantigens is chemically synthesized via in vitro transcription (IVT), encapsulated within Moderna’s proprietary lipid nanoparticles (LNPs), and subjected to automated sterile release testing.
- Site-of-Care Administration: The patient-specific vial is shipped back to the treating cancer center. The patient receives 1 mg intramuscularly every three weeks for up to 9 doses, administered alongside intravenous pembrolizumab infusions.
This complex supply chain resembles the operational choreography of autologous CAR-T cell therapy rather than off-the-shelf monoclonal antibodies, creating distinct turnaround and logistics constraints for clinical cancer centers.
The broader INTerpath program: 12 registrations and one termination
INTerpath-001 in melanoma is merely the lead trial in an aggressive, cross-tumor pipeline expansion.
To map the entire platform, we analyzed the ClinicalTrials.gov relational dataset (snapshot 2026-07-24; 595,630 total studies), identifying 12 distinct registrations for intismeran autogene / V940 / mRNA-4157:
| Study Identifier | Trial Name & Design Phase | Target Tumor Indication & Setting | Enrollment Target | Treatment Arms & Regimen | ClinicalTrials.gov Status (2026-07-24 Snapshot) |
|---|---|---|---|---|---|
| NCT05933577 | INTerpath-001 (Phase 3) | Resected High-Risk Stage IIB–IV Melanoma | 1,089 (1,137 actual) | Intismeran (1 mg IM Q3W) + Keytruda (400 mg IV Q6W) vs Keytruda | ACTIVE_NOT_RECRUITING (Topline Positive Aug 19, 2026) |
| NCT06077760 | INTerpath-002 (Phase 3) | Adjuvant Completely Resected Stage II–IIIB Non-Small Cell Lung Cancer (NSCLC) | 868 | Intismeran (1 mg IM Q3W) + Keytruda (400 mg IV Q6W) vs Keytruda | RECRUITING (Primary completion est. June 2030) |
| NCT06623422 | INTerpath-009 (Phase 3) | Adjuvant NSCLC Following Neoadjuvant Treatment (Incomplete Response) | 680 | Pembrolizumab + Intismeran vs Pembrolizumab + Placebo | RECRUITING |
| NCT07513376 | INTerpath-014 (Phase 3) | High-Risk Stage I NSCLC (Evaluating SubQ Coformulation) | 876 | Intismeran + Coformulated SubQ Pembrolizumab (QLEX) vs Pembrolizumab Alone | RECRUITING |
| NCT06307431 | INTerpath-004 (Phase 2) | Adjuvant Renal Cell Carcinoma (RCC) | 272 | Intismeran + Pembrolizumab vs Placebo + Pembrolizumab | ACTIVE_NOT_RECRUITING (Fully Enrolled per Merck June 2026) |
| NCT06305767 | INTerpath-005 (Phase 1/2) | Bladder Cancer (Adjuvant and Perioperative Cohorts) | 230 | Pembrolizumab + Intismeran vs Placebo; perioperative cohort adds EV and surgery | ACTIVE_NOT_RECRUITING (Fully Enrolled per Merck June 2026) |
| NCT06295809 | Phase 2/3 cSCC | High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) | 46 | Intismeran + Keytruda vs pembrolizumab monotherapy control | TERMINATED (Registry cites "business reasons") |
| NCT03897881 | KEYNOTE-942 (Phase 2b) | Resected Stage III/IV Melanoma (Pivotal Parent Trial) | 157 | Intismeran + Keytruda vs Keytruda (5-Yr Durability Published) | ACTIVE_NOT_RECRUITING (5-year follow-up) |
┌─────────────────────────────────────────────────────────────┐
│ MODERNA / MERCK INTerpath CLINICAL FOOTPRINT │
└──────────────────────────────┬──────────────────────────────┘
│
┌──────────────────┬─────────────────────────┼─────────────────────────┬──────────────────┐
│ │ │ │ │
▼ ▼ ▼ ▼ ▼
┌──────────────────┐┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐┌──────────────────┐
│ Melanoma Ph 3 ││ NSCLC Ph 3 │ │ NSCLC Ph 3 │ │ RCC Ph 2 ││ Bladder Ph 2 │
│ INTerpath-001 ││ INTerpath-002 │ │ INTerpath-014 │ │ INTerpath-004 ││ INTerpath-005 │
│ (Topline Met) ││ (Recruiting) │ │ (SubQ Keytruda) │ │ (Fully Enrolled)││ (Fully Enrolled) │
└──────────────────┘└──────────────────┘ └──────────────────┘ └──────────────────┘└──────────────────┘
The Terminated cSCC Trial: A Reality Check the Press Releases Skip
While corporate press releases emphasize Phase 3 successes, the registry audit shows the platform is not automatically portable across all solid tumors.
ClinicalTrials.gov record NCT06295809—a Phase 2/3 study evaluating intismeran in high-risk cutaneous squamous cell carcinoma—was terminated after enrolling 46 patients. The registry cites only "business reasons" and discloses no efficacy rationale, so the termination should not be read as evidence the platform failed in that tumor; it does, however, illustrate that program breadth depends on tumor immunogenicity, mutational burden, and strategic priorities, not on the melanoma result alone. The remaining registrations not shown in the table above are earlier-phase studies: the phase 1 study (NCT03313778), a phase 2 in melanoma (INTerpath-012, NCT06961006), a phase 2 in first-line metastatic squamous NSCLC (V940-013, NCT07221474), and a phase 2 with BCG in bladder cancer (INTerpath-011, NCT06833073).
For comparative analysis of other novel melanoma modalities, see our review of melanoma oncolytic immunotherapy access.
How the 2028 Keytruda patent cliff reshapes the commercial strategy
To understand why Merck is co-funding the INTerpath program at scale, one must look at the commercial timeline of the underlying checkpoint inhibitor backbone.
┌─────────────────────────────────────────────────────────────┐
│ THE 2028 KEYTRUDA REVENUE CLIFF & DEFENSE │
└──────────────────────────────┬──────────────────────────────┘
│
┌────────────────────────────────────────────┴────────────────────────────────────────────┐
│ │
▼ ▼
┌──────────────────────────────────────────────┐ ┌──────────────────────────────────────────────┐
│ The Baseline Patent Cliff (2028) │ │ The Two-Pillar Franchise Defense │
├──────────────────────────────────────────────┤ ├──────────────────────────────────────────────┤
│ • Keytruda IV U.S. LOE: 2028 │ │ Pillar 1: Subcutaneous Reformulation │
│ • Global Annual Net Sales: >$28 Billion │ │ • Keytruda QLEX (MK-3475A + Hyaluronidase) │
│ • Purple Book Status: 0 licensed biosimilars │ │ • HCPCS J-Code J9277; Shifts IV volume to SubQ│
│ today, but 6+ in Phase 3 development │ │ │
│ • Projected Generic Price Erosion: 50% - 80% │ │ Pillar 2: Bespoke Add-On Synergy │
│ over 24 to 36 months post-entry │ │ • Intismeran Autogene (mRNA-4157 / V940) │
│ │ │ • Tested with SubQ Keytruda in INTerpath-014 │
└──────────────────────────────────────────────┘ └──────────────────────────────────────────────┘
- The $28 Billion Loss of Exclusivity: Intravenous pembrolizumab’s primary U.S. composition-of-matter patents expire in 2028. While the FDA Purple Book relational database (snapshot 2026-06-11) currently shows zero licensed pembrolizumab biosimilars, at least seven developers—Samsung Bioepis, Sandoz, Celltrion, Amgen, Formycon/Zydus, Bio-Thera, and Henlius—are in clinical development or preparing U.S. submissions, on tracks ranging from full global Phase 3 programs to streamlined PK-based filings. For detailed entry modeling, see our pembrolizumab biosimilar entry timeline 2028.
- Pillar 1: The Subcutaneous Bridge (Keytruda QLEX): Merck’s primary lifecycle defense has been converting patients from intravenous infusions to subcutaneous co-formulations utilizing Halozyme’s recombinant human hyaluronidase (MK-3475A / berahyaluronidase alfa; assigned HCPCS code J9277). For administration and conversion economics, see our Keytruda QLEX subcutaneous access analysis.
- Pillar 2: The Bespoke Add-On (Intismeran): Intismeran provides Merck with a patent-clean, un-biosimilarizable therapeutic add-on. Crucially, INTerpath-014 (NCT07513376) explicitly combines intismeran autogene directly with the subcutaneous co-formulated pembrolizumab.
By the time pembrolizumab biosimilars enter the market in 2028–2029, Merck aims to have established that optimal cancer recurrence prevention requires combining subcutaneous pembrolizumab with custom mRNA vaccination—preserving high-margin franchise value even as the IV PD-1 molecule commoditizes.
Payer coverage, coding, and site-of-care reimbursement challenges
When intismeran autogene reaches the commercial market (projected for late 2027 or 2028), oncology pharmacy directors and medical benefit managers will confront unprecedented reimbursement questions:
┌─────────────────────────────────────────────────────────────┐
│ PAYER & REIMBURSEMENT ARCHITECTURE FOR INT │
└──────────────────────────────┬──────────────────────────────┘
│
┌────────────────────────────────────────────┼────────────────────────────────────────────┐
│ │ │
▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│ Benefit Type │ │ Coding & Admin │ │ Combination Cost │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│ Medical Benefit │ │ Permanent HCPCS │ │ How will payers │
│ Buy-and-bill or │ │ J-Code required; │ │ adjudicate INT │
│ white-bagging via│ │ CPT codes for │ │ premium on top │
│ specialty hub │ │ NGS sequencing │ │ of biosimilar? │
└──────────────────┘ └──────────────────┘ └──────────────────┘
1. Benefit Structure and Distribution Routing
Because intismeran is an intramuscular injection administered by healthcare providers in oncology clinics alongside systemic PD-1 therapy, it will be reimbursed under the medical benefit rather than the retail pharmacy benefit (Part D). Distribution will likely flow through specialized hub networks using dedicated cold-chain white-bagging or specialty buy-and-bill channels.
2. HCPCS Coding and Diagnostic Reimbursement
CMS will need to establish a dedicated permanent Healthcare Common Procedure Coding System (HCPCS) J-code for intismeran autogene. Furthermore, payers must create seamless coverage pathways for the diagnostic front-end: reimbursing the high-depth Next-Generation Sequencing (NGS) and bioinformatic analysis required to generate the mRNA blueprint before a single therapeutic dose is compounded.
3. Combination Pricing Against Generic Backbones
No price has been announced, but the scenario arithmetic is unavoidable: a bespoke per-patient product launched at the $150,000–$200,000-per-course range typical of recent adjuvant oncology entrants would sit on top of a pembrolizumab backbone whose annualized list cost (roughly $180,000 at current WAC) is expected to erode sharply once biosimilars arrive. Whether payers face a bundled combination price, separate J-codes for each component, or a premium-on-generic structure will drive medical-benefit trend in adjuvant melanoma for years.
Health plans will demand strict prior authorization criteria, limiting coverage strictly to completely resected patients who meet precise trial inclusion criteria (e.g., negative surgical margins, LDH stratification, and documented Stage IIB–IV disease).
Frequently Asked Questions
When will Merck and Moderna submit intismeran to the FDA?
The companies have said they will "engage with regulators on filing submissions" but have not announced a submission date. Detailed efficacy and safety datasets will be presented at an upcoming medical congress, and a filing that follows in 2027 would put an approval decision within reach of the 2028 loss of exclusivity window—though that timeline is inference from the trial's status, not sponsor guidance.
Is intismeran autogene regulated as a drug or a vaccine?
The sponsors have not publicly confirmed the regulatory pathway. Therapeutic cancer vaccines of this type have historically been reviewed by the FDA Center for Biologics Evaluation and Research (CBER) under Section 351 of the Public Health Service Act, which would mean a Biologics License Application (BLA); confirm the pathway when the sponsors disclose their filing.
How does intismeran differ from preventative mRNA vaccines?
Unlike preventative infectious disease vaccines (like COVID-19 or RSV vaccines) that deliver a standardized antigen sequence to healthy individuals, intismeran is a therapeutic vaccine custom-manufactured for an individual cancer patient after tumor resection, containing up to 34 neoantigens unique to that patient's tumor genome.
What happens when Keytruda patents expire in 2028?
Intravenous pembrolizumab loses U.S. patent exclusivity in 2028, opening the market to biosimilar competition. However, intismeran autogene carries its own independent patent estate. Furthermore, Merck's newer Phase 3 trial (INTerpath-014) is pairing intismeran with its proprietary subcutaneous pembrolizumab coformulation (Keytruda QLEX), ensuring continued proprietary combination exclusivity.
Which other cancer types are being tested in the INTerpath program?
Beyond melanoma, Merck and Moderna are evaluating intismeran in late-stage Phase 3 trials for adjuvant non-small cell lung cancer (INTerpath-002, INTerpath-009, and INTerpath-014), and in earlier-phase trials for adjuvant renal cell carcinoma (INTerpath-004) and bladder cancer (INTerpath-005). A Phase 2/3 trial in cutaneous squamous cell carcinoma (NCT06295809) was terminated.
Sources
- Merck & Co., Inc. and Moderna, Inc. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA (pembrolizumab) Met Primary Endpoint of Recurrence-Free Survival and Key Secondary Endpoint of Distant Metastasis-Free Survival in Patients with Resected High-Risk Stage IIB-IV Melanoma. Business Wire Press Release, August 19, 2026.
https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient - ClinicalTrials.gov. A Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab in Participants With Resected High-Risk Melanoma (INTerpath-001). Identifier: NCT05933577. Sponsor: Merck Sharp & Dohme LLC.
https://clinicaltrials.gov/study/NCT05933577 - Merck & Co., Inc. and Moderna, Inc. Moderna and Merck Present 5-Year Data for Intismeran Autogene (mRNA-4157/V940) in Combination with KEYTRUDA (pembrolizumab) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection at ASCO 2026. Corporate Press Release, June 1, 2026.
https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the20 - Journal of Clinical Oncology (JCO). Carlino, M.S. et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study. J Clin Oncol, 2026. DOI: 10.1200/JCO-26-00835.
https://ascopubs.org/doi/10.1200/JCO-26-00835 - ClinicalTrials.gov. A Study of Adjuvant Intismeran Autogene (V940) Plus Pembrolizumab in Completely Resected Stage II-IIIB Non-Small Cell Lung Cancer (INTerpath-002). Identifier: NCT06077760.
https://clinicaltrials.gov/study/NCT06077760 - ClinicalTrials.gov. A Study of Intismeran Autogene (V940) Plus Pembrolizumab in Completely Resected High-Risk Cutaneous Squamous Cell Carcinoma. Identifier: NCT06295809 (Status: Terminated).
https://clinicaltrials.gov/study/NCT06295809 - U.S. Food and Drug Administration (FDA). Purple Book: Database of Licensed Biological Products. (Biological reference record for pembrolizumab BLA 125514; relational snapshot 2026-06-11).
https://purplebooksearch.fda.gov/ - American Society of Clinical Oncology (ASCO). Study Design Abstract: Phase 3 Trial of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab in Stage II-IIIB Non-Small Cell Lung Cancer (INTerpath-002). ASCO Abstract 238530.
https://www.asco.org/abstracts-presentations/238530 - Moderna, Inc. Moderna Investor Relations: Key Pipeline Updates and Commercial Scaling for Individualized Neoantigen Therapy Platform. Corporate Presentation, August 2026.
https://www.modernatx.com/ir-insights-phase-3-intesmeran
